Home›Trial›NCT06154447
🔬NCT06154447Phase 1RECRUITING

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Study Summary

The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).

Conditions
Cystic Fibrosis
Interventions / Drugs
VX-828PlaceboItraconazoleMidazolamTezacaftorVX-118PlaceboDeutivacaftorVX-828
View on ClinicalTrials.gov ↗
Sponsor
VRTX
Vertex Pharmaceuticals
Gene Therapy
C55/100
Study Details
Enrollment255 participants
Primary Completion—
Lead SponsorVertex Pharmaceuticals Incorporated
Data Retrieved2026-04-11 02:55:58.035101+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.